Skip to main content

Optum Rx Drug Pipeline Insights Reports

Read the most recent quarterly reports on new drugs coming down the pipeline.

/content/dam/o4-dam/user-guide/images/mother-son-computer-720x460.jpg

Your source for what’s new and important in the drug industry

It used to be that new drugs coming to market could be left to medical professionals and other specialists. That’s no longer the case.

Now, every day seems to bring news of some startling advance. New drugs and drug technologies are revolutionizing medical practice — and breaking budgets. That affects everyone, including doctors, patients and especially those who must pay.

The Optum Rx Drug Pipeline Insights Report can help keep you up to date. Biologics, biosimilars, gene therapies, orphan drugs, lower-cost generics — we cover the most critical developments.

Our most recent reports are available for download, below. Check back on a quarterly basis for the latest drugs to watch.

New options to treat schizophrenia, COPD

This edition of the Drug Pipeline Insights Report showcases:

  • A new mechanism for schizophrenia with reduced side effects
  • An expanded drug indication for top 10 seller, Dupixent: COPD

Download now

 

Don't want to read the full report? View the summary.

View summary

New innovative treatments for hemophilia B, RSV, COPD

Cutting-edge research in gene therapy, mRNA editing and blood enzymes pays off with powerful new advances for these drug classes.

Winter: First big drugs for 2024

New treatments for NASH, schizophrenia and more are on the way.

Fall 2023: Exciting advances for sickle cell, chronic obesity, Alzheimer’s

See potential cures for sickle cell and new help for chronic obesity and Alzheimer’s, along with how they work and how much they cost.